183 531

Cited 10 times in

Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study

DC Field Value Language
dc.contributor.authorHong, BK-
dc.contributor.authorPark, CG-
dc.contributor.authorKim, KS-
dc.contributor.authorYoon, MH-
dc.contributor.authorYoon, HJ-
dc.contributor.authorYoon, JH-
dc.contributor.authorYang, JY-
dc.contributor.authorChoi, YJ-
dc.contributor.authorCho, SY-
dc.date.accessioned2013-04-22T05:48:51Z-
dc.date.available2013-04-22T05:48:51Z-
dc.date.issued2012-
dc.identifier.issn1175-3277-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/7794-
dc.description.abstractBACKGROUND: Fixed-dose combination drugs may enhance blood pressure (BP) goal attainment through complementary effects and reduced side effects, which leads to better compliance.



OBJECTIVE: This study aimed to evaluate the efficacy and safety profiles of once-daily combination amlodipine/losartan versus losartan.



METHODS: This was an 8-week, double-blind, multicenter, randomized phase III study conducted in outpatient hospital clinics. Korean patients with essential hypertension inadequately controlled on losartan 100 mg were administered amlodipine/losartan 5 mg/100 mg combination versus losartan 100 mg. The main outcome measures were changes in sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP) and BP response rate from baseline values, which were assessed after 4 and 8 weeks of treatment. Safety and tolerability were also assessed.



RESULTS: At week 8, both groups achieved significant reductions from baseline in DBP (11.7 ± 7.0 and 3.2 ± 7.9 mmHg), which was significantly greater in the amlodipine/losartan 5 mg/100 mg combination (n = 70) group (p < 0.0001). Additionally, the amlodipine/losartan 5 mg/100 mg combination group achieved significantly greater reductions in SBP at week 8 and in SBP and DBP at week 4 compared with the losartan 100 mg (n = 72) group (all p < 0.0001). Response rates were significantly higher in the amlodipine/losartan 5 mg/100 mg group versus the losartan 100 mg group (81.4% vs 63.9% at week 4, p < 0.0192; 90.0% vs 66.7% at week 8, p < 0.001). Both treatments were generally well tolerated.



CONCLUSION: Switching to a fixed-dose combination therapy of amlodipine/losartan 5 mg/100 mg was associated with significantly greater reductions in BP and superior achievement of BP goals compared with a maintenance dose of losartan 100 mg in Korean patients with essential hypertension inadequately controlled on losartan 100 mg.



CLINICAL TRIAL REGISTRATION: Registered at Clinicaltrials.gov as NCT00940680.
-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAmlodipine/administration & dosage/adverse effects/*therapeutic use-
dc.subject.MESHAmlodipine/administration & dosage/adverse effects/*therapeutic use effects/therapeutic use-
dc.subject.MESHAntihypertensive Agents/administration & dosage/adverse effects/*therapeutic use-
dc.subject.MESHBlood Pressure/drug effects-
dc.subject.MESHCalcium Channel Blockers/administration & dosage/adverse effects/therapeutic use-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHDrug Combinations-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHHypertension/*drug therapy/physiopathology-
dc.subject.MESHLosartan/administration & dosage/adverse effects/*therapeutic use-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.titleComparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study-
dc.typeArticle-
dc.identifier.pmid22462558-
dc.contributor.affiliatedAuthor윤, 명호-
dc.type.localJournal Papers-
dc.identifier.doi10.2165/11597410-000000000-00000-
dc.citation.titleAmerican journal of cardiovascular drugs : drugs, devices, and other interventions-
dc.citation.volume12-
dc.citation.number3-
dc.citation.date2012-
dc.citation.startPage189-
dc.citation.endPage195-
dc.identifier.bibliographicCitationAmerican journal of cardiovascular drugs : drugs, devices, and other interventions, 12(3):189-195, 2012-
dc.identifier.eissn1179-187X-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Cardiology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse